Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 6
1977 3
1978 1
1979 2
1980 4
1981 10
1982 7
1983 1
1984 8
1985 7
1986 6
1987 3
1988 4
1989 3
1990 3
1991 2
1992 1
1993 2
1994 6
1995 4
1996 5
1997 7
1998 6
1999 5
2000 3
2001 5
2002 5
2003 4
2004 2
2005 3
2006 3
2008 3
2009 1
2010 2
2011 3
2012 1
2013 1
2016 2
2017 1
2018 4
2019 4
2020 3
2021 7
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma.
Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, Demeter J, Smythe KS, Pierce RH, Fling SP, Ramchurren N, Cheever MA, Goltsev Y, West RB, Khodadoust MS, Kim YH, Schürch CM, Nolan GP. Phillips D, et al. Among authors: cheever ma. Nat Commun. 2021 Nov 18;12(1):6726. doi: 10.1038/s41467-021-26974-6. Nat Commun. 2021. PMID: 34795254 Free PMC article. Clinical Trial.
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Byrne KT, et al. Among authors: cheever ma. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. Clin Cancer Res. 2021. PMID: 34112709 Free PMC article. Clinical Trial.
Designing HER2 vaccines.
Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA. Foy TM, et al. Among authors: cheever ma. Semin Oncol. 2002 Jun;29(3 Suppl 11):53-61. doi: 10.1053/sonc.2002.34056. Semin Oncol. 2002. PMID: 12138398 Review.
Immunity to oncogenic proteins.
Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Cheever MA, et al. Immunol Rev. 1995 Jun;145:33-59. doi: 10.1111/j.1600-065x.1995.tb00076.x. Immunol Rev. 1995. PMID: 7590829 Review. No abstract available.
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff MS, Gastman BR, Hanks BA, Curti BD, Albertini MR, Luke JJ, Blazquez AB, Balan S, Bedognetti D, Beechem JM, Crocker AS, D'Amico L, Danaher P, Davis TA, Hawthorne T, Hess BW, Keler T, Lundgren L, Morishima C, Ramchurren N, Rinchai D, Salazar AM, Salim BA, Sharon E, Vitale LA, Wang E, Warren S, Yellin MJ, Disis ML, Cheever MA, Fling SP. Bhardwaj N, et al. Among authors: cheever ma. Nat Cancer. 2020 Dec;1(12):1204-1217. doi: 10.1038/s43018-020-00143-y. Epub 2020 Nov 16. Nat Cancer. 2020. PMID: 35121932 Clinical Trial.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Nghiem P, et al. Among authors: cheever ma. J Immunother Cancer. 2021 Apr;9(4):e002478. doi: 10.1136/jitc-2021-002478. J Immunother Cancer. 2021. PMID: 33879601 Free PMC article. Clinical Trial.
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Odunsi K, et al. Among authors: cheever ma. Sci Transl Med. 2022 Mar 16;14(636):eabg8402. doi: 10.1126/scitranslmed.abg8402. Epub 2022 Mar 16. Sci Transl Med. 2022. PMID: 35294258 Free PMC article.
In vivo administration of interleukin-2.
Cheever MA, Greenberg PD. Cheever MA, et al. Contemp Top Mol Immunol. 1985;10:263-82. doi: 10.1007/978-1-4684-4838-2_11. Contemp Top Mol Immunol. 1985. PMID: 3884257 Review. No abstract available.
164 results